Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.
Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM, Mareschal S, Alcantara M, Bouzelfen A, Dubois S, Figeac M, Bastard C, Tilly H, Jardin F. Bertrand P, et al. Among authors: alcantara m. Genes Chromosomes Cancer. 2013 Aug;52(8):764-74. doi: 10.1002/gcc.22072. Epub 2013 May 28. Genes Chromosomes Cancer. 2013. PMID: 23716461
HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations.
Bouzelfen A, Alcantara M, Kora H, Picquenot JM, Bertrand P, Cornic M, Mareschal S, Bohers E, Maingonnat C, Ruminy P, Adriouch S, Boyer O, Dubois S, Bastard C, Tilly H, Latouche JB, Jardin F. Bouzelfen A, et al. Among authors: alcantara m. Leuk Res. 2016 Jun;45:90-100. doi: 10.1016/j.leukres.2016.04.007. Epub 2016 Apr 11. Leuk Res. 2016. PMID: 27107267
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, Guidez S, Gastinne T, Canioni D, Thieblemont C, Maisonneuve H, Bodet-Milin C, Houot R, Oberic L, Bouabdallah K, Bescond C, Damaj G, Jaccard A, Daguindau N, Moreau A, Tilly H, Ribrag V, Delfau-Larue MH, Hermine O, Macintyre E. Le Gouill S, et al. Among authors: alcantara m. Lancet Haematol. 2020 Nov;7(11):e798-e807. doi: 10.1016/S2352-3026(20)30291-X. Epub 2020 Sep 21. Lancet Haematol. 2020. PMID: 32971036 Clinical Trial.
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins.
Steimlé T, Dourthe ME, Alcantara M, Touzart A, Simonin M, Mondesir J, Lhermitte L, Bond J, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Balsat M, Vey N, Macintyre E, Ifrah N, Dombret H, Petit A, Baruchel A, Ruminy P, Boissel N, Asnafi V. Steimlé T, et al. Among authors: alcantara m. Blood Cancer J. 2022 Jan 26;12(1):14. doi: 10.1038/s41408-022-00613-9. Blood Cancer J. 2022. PMID: 35082269 Free PMC article.
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. J Hematol Oncol. 2024 Sep 19;17(1):86. doi: 10.1186/s13045-024-01606-w. J Hematol Oncol. 2024. PMID: 39300447 Free PMC article. Clinical Trial.
269 results